Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on three disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV).
Type | Public | |
Founded | 1998 | |
HQ | Watertown, MA, US | Map |
Website | enanta.com | |
Employee Ratings | More | |
Overall Culture | F | More |
USD | |
---|---|
Revenue (Q1, 2021) | 31.7m |
Net income (Q1, 2021) | (8.3m) |
EBIT (Q1, 2021) | (12.3m) |
Market capitalization (26-Feb-2021) | 994.9m |
Closing stock price (26-Feb-2021) | 49.3 |
Cash (31-Dec-2020) | 55.1m |
EV | 948.5m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.2m | 1.6m | 893.0k | 2.2m | 42.1m | 77.5m | 57.4m | 11.6m | 48.4m | 13.0m | 14.0m | 10.4m | 9.0m | 7.5m | 38.1m | 44.0m | 57.3m | 69.9m | 39.6m | 44.4m | 52.6m | 27.6m | 18.7m | 31.7m |
General and administrative expense | 1.5m | 1.8m | 2.1m | 2.6m | 2.6m | 2.8m | 3.4m | 3.6m | 3.8m | 4.4m | 4.3m | 4.9m | 5.5m | 5.2m | 5.8m | 5.7m | 6.1m | 7.2m | 6.8m | 6.2m | 6.9m | 6.9m | 6.8m | 7.4m |
R&D expense | 3.7m | 4.0m | 4.3m | 4.7m | 4.6m | 4.5m | 5.4m | 6.3m | 9.0m | 9.1m | 10.8m | 12.5m | 13.0m | 15.4m | 18.0m | 21.5m | 28.5m | 34.9m | 34.2m | 34.5m | 32.8m | 32.6m | 34.7m | 36.7m |
Operating expense total | 5.2m | 5.8m | 6.4m | 7.3m | 7.2m | 7.3m | 8.8m | 9.9m | 12.9m | 13.6m | 15.1m | 17.5m | 18.5m | 20.6m | 23.7m | 27.2m | 34.6m | 42.0m | 40.9m | 40.6m | 39.7m | 39.5m | 41.5m | 44.0m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 74.5m | 18.9m | 4.4m | 18.1m | 26.4m | 34.1m | 25.8m | 19.8m | 46.2m | 56.4m | 24.8m | 20.6m | 19.2m | 22.3m | 68.1m | 66.9m | 42.5m | 74.4m | 106.0m | 94.2m | 27.6m | 74.3m | 99.9m | 55.1m |
Accounts Receivable | 669.0k | 876.0k | 279.0k | 998.0k | 399.0k | 76.6m | 7.1m | 11.7m | 17.9m | 13.0m | 14.0m | 10.4m | 9.0m | 7.5m | 23.1m | 44.0m | 57.3m | 69.9m | 39.6m | 44.4m | 52.6m | 27.6m | 18.7m | 31.7m |
Prepaid Expenses | 1.1m | 1.5m | 1.3m | 2.0m | 2.0m | 1.2m | 2.2m | 3.5m | 8.5m | 7.7m | 8.2m | 4.3m | 6.1m | 6.6m | 4.1m | 4.9m | 9.4m | 7.6m | 14.1m | 17.6m | 14.2m | 19.8m | 24.7m | 28.0m |
Current Assets | 111.7m | 97.9m | 94.4m | 99.3m | 111.7m | 185.1m | 177.8m | 172.6m | 209.0m | 242.7m | 241.8m | 224.1m | 190.6m | 206.1m | 247.6m | 305.7m | 339.9m | 423.3m | 423.8m | 451.3m | 440.5m | 402.7m | 413.4m | 445.9m |
USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|
Net Income | 9.6m | 34.4m | 79.0m | 21.7m | 17.7m | 72.0m | 46.4m | (36.2m) |
Depreciation and Amortization | 221.0k | 352.0k | 639.0k | 1.7m | 2.1m | 2.5m | 3.3m | 3.6m |
Accounts Payable | 115.0k | 399.0k | (543.0k) | 1.5m | 633.0k | 1.3m | 1.8m | (883.0k) |
Cash From Operating Activities | 10.7m | 20.2m | 76.7m | 35.8m | 52.7m | 29.2m | 71.4m | 7.1m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 18.2m | 14.1m | (5.4m) | (10.6m) | 39.5m | 42.0m | 70.8m | 73.2m | 26.2m | 24.5m | 23.5m | (5.0m) | (10.4m) | (18.8m) | 11.7m | 24.2m | 44.5m | 26.0m | 30.2m | 37.2m | 13.4m | 7.4m | (6.8m) | (8.3m) |
Depreciation and Amortization | 87.0k | 148.0k | 75.0k | 154.0k | 242.0k | 129.0k | 270.0k | 435.0k | 339.0k | 772.0k | 1.2m | 493.0k | 1.0m | 1.6m | 587.0k | 1.2m | 1.9m | 680.0k | 1.5m | 2.4m | 904.0k | 1.8m | 2.7m | 871.0k |
Accounts Payable | (469.0k) | (620.0k) | (648.0k) | 316.0k | (190.0k) | (1.3m) | 488.0k | (332.0k) | 149.0k | 1.2m | 677.0k | (1.3m) | 688.0k | 2.7m | (129.0k) | 565.0k | 1.4m | 124.0k | 2.9m | 1.6m | (179.0k) | (731.0k) | (672.0k) | 575.0k |
Cash From Operating Activities | 19.1m | 13.2m | (5.9m) | (10.0m) | 25.1m | (5.6m) | 93.3m | 79.0m | 30.0m | 40.0m | 37.9m | 3.1m | 143.0k | (4.7m) | 4.4m | (3.2m) | 879.0k | 30.3m | 60.3m | 62.9m | 12.4m | 27.0m | 22.5m | (14.9m) |
USD | Q2, 2013 |
---|---|
Financial Leverage | 1.1 x |
F
43/100
F
10/100
A+
100/100
When was Enanta Pharmaceuticals founded?
Enanta Pharmaceuticals was founded in 1998.
Who are Enanta Pharmaceuticals key executives?
Enanta Pharmaceuticals's key executives are Jay R. Luly, Yat Sun Or and Brendan Luu.
How many employees does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 132 employees.
What is Enanta Pharmaceuticals revenue?
Latest Enanta Pharmaceuticals annual revenue is $205.2 m.
What is Enanta Pharmaceuticals revenue per employee?
Latest Enanta Pharmaceuticals revenue per employee is $1.6 m.
Who are Enanta Pharmaceuticals competitors?
Competitors of Enanta Pharmaceuticals include Frequency Therapeutics, Biohaven Pharmaceutical and Lodo Therapeutics.
Where is Enanta Pharmaceuticals headquarters?
Enanta Pharmaceuticals headquarters is located at 500 Arsenal St, Watertown.
Where are Enanta Pharmaceuticals offices?
Enanta Pharmaceuticals has an office in Watertown.
How many offices does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 2 offices.
Receive alerts for 300+ data fields across thousands of companies